Royal Bank of Canada boosted its stake in shares of Invesco Biotechnology & Genome ETF (NYSEARCA:PBE – Free Report) by 25.9% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 59,329 shares of the company’s stock after purchasing an additional 12,215 shares during the quarter. Royal Bank of Canada owned about 1.91% of Invesco Biotechnology & Genome ETF worth $4,698,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in PBE. Raymond James Financial Inc. lifted its stake in shares of Invesco Biotechnology & Genome ETF by 1.8% in the third quarter. Raymond James Financial Inc. now owns 8,078 shares of the company’s stock worth $564,000 after buying an additional 141 shares during the last quarter. NewEdge Advisors LLC grew its stake in Invesco Biotechnology & Genome ETF by 18.1% in the 4th quarter. NewEdge Advisors LLC now owns 1,043 shares of the company’s stock valued at $86,000 after buying an additional 160 shares during the last quarter. Comerica Bank grew its stake in Invesco Biotechnology & Genome ETF by 86.2% in the 4th quarter. Comerica Bank now owns 378 shares of the company’s stock valued at $31,000 after buying an additional 175 shares during the last quarter. PNC Financial Services Group Inc. raised its holdings in Invesco Biotechnology & Genome ETF by 74.5% in the 3rd quarter. PNC Financial Services Group Inc. now owns 574 shares of the company’s stock worth $40,000 after acquiring an additional 245 shares during the period. Finally, Colonial Trust Advisors bought a new position in Invesco Biotechnology & Genome ETF in the 4th quarter worth $25,000.
Invesco Biotechnology & Genome ETF Price Performance
Invesco Biotechnology & Genome ETF stock opened at $94.22 on Friday. The firm has a market cap of $296.79 million, a price-to-earnings ratio of 20.44 and a beta of 0.70. Invesco Biotechnology & Genome ETF has a fifty-two week low of $66.81 and a fifty-two week high of $95.01. The firm has a fifty day moving average price of $89.26 and a two-hundred day moving average price of $83.69.
Invesco Biotechnology & Genome ETF Company Profile
PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.
See Also
- Five stocks we like better than Invesco Biotechnology & Genome ETF
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for Invesco Biotechnology & Genome ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invesco Biotechnology & Genome ETF and related companies with MarketBeat.com's FREE daily email newsletter.
